Investigating the effects of a self-guided, internet-based self-help program for people with anxiety disorders

Effects of a Self-Guided Transdiagnostic Internet Intervention (velibra) for Anxiety Disorders in Primary Care: A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN81412545

Enrollment

300

Registered

2016-02-26

Start date

2014-05-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety Disorder: Social Anxiety Disorder, Panic Disorder with/without Agoraphobia and/or Generalized Anxiety Disorder Mental and Behavioural Disorders Anxiety Disorder

Interventions

Participants are randomly allocated to one of two groups. A stratified randomization procedure will be applied such that a balanced distribution of primary diagnostic groups in the two conditions will

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Written informed consent 2. Written declaration of no objection signed by a medical doctor 3. Aged 18 years or over 4. Access to the Internet 5. Sufficient knowledge of German 6. Primary diagnosis of Social Anxiety Disorder, Panic Disorder with/without Agoraphobia, or Generalized Anxiety Disorder according to DSM-IV (assessed with a clinical interview)

Exclusion criteria

Exclusion criteria: 1. History of a psychotic or bipolar disorder 2. Suicidal ideation or plans (assessed by the suicide item of the Beck Depression Inventory and in a diagnostic interview)

Design outcomes

Primary

Measure	Time frame
Depression, anxiety and tension/stress is measured using Depression Anxiety Stress Scales (DASS-21) at baseline, 9 weeks and 6 months.	—

Secondary

Measure	Time frame
1. Diagnostic status is determined using the Structured Clinical Interview for DSM Disorders (SCID-I) at baseline and 9 weeks 2. Depression, anxiety and tension/stress is measured using the Depression Anxiety Stress Scales (DASS-21) at baseline and 6 months 3. Anxiety is measured using the Beck Anxiety Inventory (BAI) at baseline, 9 weeks and 6 months 4. Depression is measured using the Beck Depression Inventory (BDI-II) at baseline, 9 weeks and 6 months 5. General symptomatology is measured using the Brief Symptom Inventory (BSI) at baseline, 9 weeks and 6 months 6. Social Anxiety is measured using the Social Phobia Scale (SPS) at baseline, 9 weeks and 6 months 7. Social Anxiety is measured using the Social Interaction Anxiety Scale (SIAS) at baseline, 9 weeks and 6 months 8. Agoraphobic cognitions are measured using the Agoraphobic Cognitions Questionnaire (ACQ) at baseline, 9 weeks and 6 months 9. Fear of body sensations is measured using the Body Sensations Questionnaire (BSQ) at baseline, 9 weeks and 6 months 10. Agoraphobic avoidance is measured using the Mobility Inventory (MIA & MIB) at baseline, 9 weeks and 6 months 11. Worry severity is measured using the Penn State Worry Questionnaire (PSWQ) at baseline, 9 weeks and 6 months	—

Measure

Time frame

1. Diagnostic status is determined using the Structured Clinical Interview for DSM Disorders (SCID-I) at baseline and 9 weeks 2. Depression, anxiety and tension/stress is measured using the Depression Anxiety Stress Scales (DASS-21) at baseline and 6 months 3. Anxiety is measured using the Beck Anxiety Inventory (BAI) at baseline, 9 weeks and 6 months 4. Depression is measured using the Beck Depression Inventory (BDI-II) at baseline, 9 weeks and 6 months 5. General symptomatology is measured using the Brief Symptom Inventory (BSI) at baseline, 9 weeks and 6 months 6. Social Anxiety is measured using the Social Phobia Scale (SPS) at baseline, 9 weeks and 6 months 7. Social Anxiety is measured using the Social Interaction Anxiety Scale (SIAS) at baseline, 9 weeks and 6 months 8. Agoraphobic cognitions are measured using the Agoraphobic Cognitions Questionnaire (ACQ) at baseline, 9 weeks and 6 months 9. Fear of body sensations is measured using the Body Sensations Questionnaire (BSQ) at baseline, 9 weeks and 6 months 10. Agoraphobic avoidance is measured using the Mobility Inventory (MIA & MIB) at baseline, 9 weeks and 6 months 11. Worry severity is measured using the Penn State Worry Questionnaire (PSWQ) at baseline, 9 weeks and 6 months

—

Countries

Austria, Germany, Switzerland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026